This technology includes the use of cyclooxygenase-2 (COX-2) inhibitors for the treatment of serum amyloid A (SAA)-high asthma. A commercially available enzyme-linked immunosorbent assay was used to analyze serum levels of SAA in a cohort of 154 non-asthmatic subjects to establish the upper 95th centile value of serum SAA in healthy individuals as > 108.843 ug/ml. RNA-seq identified that high-density lipoprotein (HDL) enriched with SAA 1 increased the expression of COX-2 in CD14+ monocytes from asthmatics, which was confirmed by Western blotting. The selective COX-2 inhibitors, celecoxib and diclofenac, both significantly inhibited HDL +SAA1-mediated secretion of IL-1 p, IL-6, TNF-a, and IL-10 by classical CD14+/CD16· monocytes. We propose that serum SAA levels > 108.843 μg/ml can be used to identify SM-high asthmatics for targeted treatment with COX-2 inhibitors in a precision medicine approach.